Hydroxychloroquin Heumann (Hydroxychloroquine Sulfate)

Hydroxychloroquine raises the pH inside lysosomes and parasite vacuoles, disrupting heme polymerization in malaria parasites. In autoimmune diseases it modulates immune cell signaling, reduces Toll‑like receptor activation, and limits cytokine release, thereby dampening inflammation.

The dosage of hydroxychloroquine is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the specific indication, patient characteristics, and clinical response.

Safety data in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydroxychloroquine is chemically related to chloroquine but generally has a better safety profile, especially regarding retinal toxicity. Compared with newer artemisinin‑based combinations, it is less potent against resistant malaria strains, but its immunomodulatory properties make it valuable for autoimmune conditions where chloroquine is less effective.

Store the product at room temperature, below 25 °C, in its original container. Protect it from moisture, excessive heat and direct sunlight. Do not use if the packaging is damaged or the tablet shows signs of discoloration.

Hydroxychloroquin Heumann is taken orally. Tablets should be swallowed whole with a full glass of water, preferably with food to reduce gastrointestinal upset. Dosing times and intervals are set by the prescribing clinician.

The most serious adverse effects include retinal toxicity leading to permanent vision loss, cardiac arrhythmias such as QT prolongation, severe hypoglycemia especially in diabetic patients, and hematologic disorders like agranulocytosis or hemolytic anemia. Regular monitoring is essential.

Patients with known hypersensitivity to hydroxychloroquine or related compounds, pre‑existing retinal disease, significant cardiac conduction abnormalities, or severe hepatic or renal impairment should avoid the drug. Use is also contraindicated in individuals where the risk outweighs the benefit, as determined by a healthcare professional.